WITHIN THE HMO INDUSTRY, Kaiser Permanente is highly respected for its thorough research into the clinical efficacy and economic cost of new healthcare technologies.
That is the reason why Kaiser’s decision to adopt NeoPath, Inc.’s automated cytology technology for primary screening of Pap smears is getting widespread attention within the laboratory community.
Coupled with a similar decision by
Subscriber-Only Content. Please Log In.
You are trying to access subscribers-only content. If you are a subscriber, please log in.
If you are not a subscriber, click here to see subscription offers.
Subscribers will have instant access to the Dark Report library, 1997 - the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!
To read our FREE article previews, go to The Dark Report Insider.